Showing paper detailed information
Citation Information
Front Oncol. 2021 May 31;11:630672. doi: 10.3389/fonc.2021.630672. eCollection 2021.
Circulating Tumor Cell and Metabolites as Novel Biomarkers for Early-Stage Lung Cancer Diagnosis.
Wan L, Liu Q, Liang D, Guo Y, Liu G, Ren J, He Y, Shan B.
Analytical methods | ||
|---|---|---|
| Comparative study | #1 | |
| Chromatography | LC | |
| Ion source | ESI | |
| Positive/Negative mode | both | |
| Mass analyzer | Q-TOF | |
| Identification level | – | |
Sample information | ||
|---|---|---|
| Comparative study | #1 | |
| Country | China | |
| Specimen | Serum | |
| Marker function | diagnosis | |
| Participants(Case) | Cancer type | squamous cell carcinoma, adenocarcinomas |
| Stage | I, II | |
| Number | 48 | |
| Gender (M,F) | 21, 27 | |
| Mean age (range) (M,F) | 59.1 (38-75) | |
| Smoking status | smoker, non-smoker | |
| Participants(Control) | Type | healthy |
| Number | 30 | |
| Gender (M,F) | – | |
| Mean age (range) (M,F) | – | |
| Smoking status | – | |
Data processing and metabolite identification | |
|---|---|
| Data processing software | Progenesis QI 2.3 |
| Database search | HMDB, Metlin |
Statistical analysis | |
|---|---|
| Differential analysis method | PCA, OPLS-DA, Student’s t test |
| Classification method | – |
| Survival analysis method | – |
Lung cancer-related metabolites identified in the paper
| Metabolite | Author-emphasized biomarkers | Mean concentration (case) | Mean concentration (control) | Fold change (case/control) | P-value | FDR | VIP |
|---|---|---|---|---|---|---|---|
| LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(16:1(9Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(18:0/20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | <0.05 | – | >1 |
| 1-linoleoylglycerophosphocholine | – | – | – | – | <0.05 | – | >1 |
| PC(16:0/20:4(5Z,8Z,11Z,14Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(18:0) | – | – | – | – | <0.05 | – | >1 |
| L-palmitoylcarnitine | – | – | – | – | <0.05 | – | >1 |
| PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(14:0/20:4(5Z,8Z,11Z,14Z)) | – | – | – | – | <0.05 | – | >1 |
| 12(R)-HETE | – | – | – | – | <0.05 | – | >1 |
| LysoPC(18:3(9Z,12Z,15Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(16:1(9Z)/0:0) | – | – | – | – | <0.05 | – | >1 |
| PC(18:1(11Z)/18:3(6Z,9Z,12Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(15:0/22:1(13Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(15:0/24:1(15Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(20:2(11Z,14Z)/18:1(11Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(16:0/20:3(5Z,8Z,11Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(14:0/20:4(5Z,8Z,11Z,14Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(15:0/22:1(13Z)) | – | – | – | – | <0.05 | – | >1 |
| PE(15:0/24:1(15Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(16:1(9Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(18:0/20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | <0.05 | – | >1 |
| L-isoleucine | – | – | – | – | <0.05 | – | >1 |
| 1-linoleoylglycerophosphocholine | – | – | – | – | <0.05 | – | >1 |
| PC(16:0/20:4(5Z,8Z,11Z,14Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(18:0) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(18:3(9Z,12Z,15Z)) | – | – | – | – | <0.05 | – | >1 |
| LysoPC(16:1(9Z)/0:0) | – | – | – | – | <0.05 | – | >1 |
| PC(18:1(11Z)/18:3(6Z,9Z,12Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(20:2(11Z,14Z)/18:1(11Z)) | – | – | – | – | <0.05 | – | >1 |
| PC(16:0/20:3(5Z,8Z,11Z)) | – | – | – | – | <0.05 | – | >1 |
| Metabolite | Author-emphasized biomarkers | Cutoff value | AUROC (95%CI) | Sensitivity (%) | Specificity (%) | Accuracy (%) |
|---|---|---|---|---|---|---|
| LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | – | – |
| LysoPC(20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | – | – |
| LysoPC(16:1(9Z)) | – | – | – | – | – | – |
| PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | – | – | – | – | – | – |
| PC(18:0/20:4(8Z,11Z,14Z,17Z)) | – | – | 0.979 | 0.9333 | 0.9333 | – |
| 1-linoleoylglycerophosphocholine | – | – | – | – | – | – |
| PC(16:0/20:4(5Z,8Z,11Z,14Z)) | – | – | 1 | 1 | 1 | – |
| PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | – | – |
| PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | 0.968 | 0.9 | 0.9667 | – |
| LysoPC(18:0) | – | – | 0.933 | 0.9333 | 0.8 | – |
| L-palmitoylcarnitine | – | – | 0.993 | 0.9333 | 1 | – |
| PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | – | – |
| PE(14:0/20:4(5Z,8Z,11Z,14Z)) | – | – | – | – | – | – |
| 12(R)-HETE | – | – | – | – | – | – |
| LysoPC(18:3(9Z,12Z,15Z)) | – | – | – | – | – | – |
| LysoPC(16:1(9Z)/0:0) | – | – | 0.951 | 0.9667 | 0.8388 | – |
| PC(18:1(11Z)/18:3(6Z,9Z,12Z)) | – | – | – | – | – | – |
| PE(15:0/22:1(13Z)) | – | – | – | – | – | – |
| PE(15:0/24:1(15Z)) | – | – | – | – | – | – |
| PC(20:2(11Z,14Z)/18:1(11Z)) | – | – | – | – | – | – |
| PC(16:0/20:3(5Z,8Z,11Z)) | – | – | – | – | – | – |
| PE(16:0/22:5(7Z,10Z,13Z,16Z,19Z)) | – | – | 1 | 1 | 1 | – |
| PE(14:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | 1 | 1 | 1 | – |
| PE(14:0/20:4(5Z,8Z,11Z,14Z)) | – | – | 1 | 1 | 1 | – |
| PE(15:0/22:1(13Z)) | – | – | – | – | – | – |
| PE(15:0/24:1(15Z)) | – | – | – | – | – | – |
| LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | – | – |
| LysoPC(20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | – | – |
| LysoPC(16:1(9Z)) | – | – | – | – | – | – |
| PC(18:2(9Z,12Z)/18:2(9Z,12Z)) | – | – | – | – | – | – |
| PC(18:0/20:4(8Z,11Z,14Z,17Z)) | – | – | – | – | – | – |
| L-isoleucine | – | – | 0.967 | 0.9333 | 0.9667 | – |
| 1-linoleoylglycerophosphocholine | – | – | – | – | – | – |
| PC(16:0/20:4(5Z,8Z,11Z,14Z)) | – | – | – | – | – | – |
| PC(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | – | – | – | – | – | – |
| LysoPC(18:0) | – | – | – | – | – | – |
| LysoPC(18:3(9Z,12Z,15Z)) | – | – | – | – | – | – |
| LysoPC(16:1(9Z)/0:0) | – | – | – | – | – | – |
| PC(18:1(11Z)/18:3(6Z,9Z,12Z)) | – | – | – | – | – | – |
| PC(20:2(11Z,14Z)/18:1(11Z)) | – | – | – | – | – | – |
| PC(16:0/20:3(5Z,8Z,11Z)) | – | – | – | – | – | – |
Paper graphical summary
